121 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
. Adverum expects its cash, cash equivalents and short-term investments to fund operations into late 2025.
Research and development expenses were … $15.4 million for the three months ended March 31, 2024, compared to $21.1 million for the same period in 2023. Research and development expenses
8-K
EX-99.1
aiqd3k 5ecngh1v6edp
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
8-K
43fj3jmfso
5 Feb 24
Entry into a Material Definitive Agreement
5:03pm
8-K/A
w8oqb49nw2
4 Dec 23
Departure of Directors or Certain Officers
4:09pm
8-K
EX-99.1
c28sx
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
ss9ps 0zqds
6 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
EX-99.1
rici5s n6r
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
424B5
7dhppih863r x5f56cg
11 May 23
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
twcmoea0agkmzb1 6a9
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm
PRE 14A
fnynliqna3veqdeuwzc
14 Apr 23
Preliminary proxy
6:03am